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Clinical investigations prove that blue light irradiation reduces the severity of psoriasis
vulgaris. Nevertheless, the mechanisms involved in the management of this condition
remain poorly defined. Despite the encouraging results of the clinical studies, no clear
guidelines are specified in the literature for the irradiation scheme regime of blue
light-based therapy for psoriasis. We investigated the underlying mechanism of blue light
irradiation of psoriatic skin, and tested the hypothesis that regulation of proliferation is a
key process. We implemented a mechanistic model of cellular epidermal dynamics to
analyze whether a temporary decrease of keratinocytes hyper-proliferation can explain
the outcome of phototherapy with blue light. Our results suggest that the main effect of
blue light on keratinocytes impacts the proliferative cells. They show that the decrease
in the keratinocytes proliferative capacity is sufficient to induce a transient decrease in
the severity of psoriasis. To study the impact of the therapeutic regime on the efficacy of
psoriasis treatment, we performed simulations for different combinations of the treatment
parameters, i.e., length of treatment, fluence (also referred to as dose), and intensity.
These simulations indicate that high efficacy is achieved by regimes with long duration
and high fluence levels, regardless of the chosen intensity. Our modeling approach
constitutes a framework for testing diverse hypotheses on the underlying mechanism
of blue light-based phototherapy, and for designing effective strategies for the treatment
of psoriasis.
Keywords: inflammatory skin conditions, epidermis, keratinocytes, computational model, phototherapy, visible
light
INTRODUCTION
Blue light (BL) at 453 nm is non-toxic (Awakowicz et al., 2009; Kleinpenning et al., 2010) and
decreases the symptoms of psoriasis vulgaris (Pv) (Weinstabl et al., 2011; Pfaff et al., 2015), a
chronic, inflammatory skin condition that affects 2–3% of the world’s population (Parisi et al.,
2013). Psoriasis vulgaris is characterized by hyper proliferation and lowered differentiation of skin
Abbreviations: BL, Blue Light; Pv, Psoriasis vulgaris; F, Fluence; UV, Ultraviolet light; BLISS, Computational model for Blue
Light Irradiation of Psoriatic Skin; Psc, Stem Cells; Pta, Transit Amplifying cells; Pga, Growth Arrested cells; Psp, Spinous cells;
Pgc, Granular Cells; Pcc, Corneocytes; Iav, Average power density; CW, Continuous Wave mode; PW, Pulsed Wave mode; Ip,
Peak power density; PASI, Psoriasis Area and Severity Index; LPSI, Local Psoriasis Severity Index; MPSA, Multiple parameter
sensitivity analysis; LPSA, Local sensitivity analysis; LI, Low Intensity; HI, High Intensity.
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keratinocytes (Weinstein et al., 1985), evident in lesional areas
of thick skin (Perera et al., 2012). These areas also exhibit
sustained inflammation caused by immune cells such as T cells
and dendritic cells (Perera et al., 2012). Blue light minimizes the
proliferation of keratinocytes and induces their differentiation in
a wavelength and fluence dependent manner (Liebmann et al.,
2010). Additionally, blue light irradiation suppresses dendritic
cell activation (Fischer et al., 2013). These effects of blue light
on keratinocytes and immune cells may explain the reduced
inflammation and diminished epidermal thickness of lesional
psoriatic skin after the treatment. Nevertheless, the underlying
mechanism of this therapeutic approach is not fully understood.
It is not clear how the cellular processes of proliferation and
differentiation are modified in the cells after irradiation with
blue light. Further, it is uncertain whether blue light affects only
proliferative cells or both proliferative and non-proliferative cells.
It is hypothesized that BL improves psoriatic skin by decreasing
the proliferative capacity of keratinocytes.
Large variations are observed in the results from the available
clinical investigations (Maari et al., 2003; Weinstabl et al., 2011;
Kleinpenning et al., 2012; Pfaff et al., 2015). These discrepancies
in the reported outcome may be due to differences in the main
treatment parameters, i.e. length of treatment (days), fluence F
(Jcm−2) also referred to as dose, and power density (mWcm−2)
also denoted as intensity. Additionally, a BL treatment session
may occur one or more times per week for a certain number
of weeks (Maari et al., 2003; Weinstabl et al., 2011). Despite
all the potential combinations of treatment parameters and
their impact on the effectiveness of the treatment, the effect of
variations in the irradiation parameters of BL on the dynamics
of keratinocytes is unknown. Additionally, no clear guidelines
have been defined in the literature for BL treatment of psoriasis.
The current treatments for psoriasis include phototherapy with
ultraviolet (UV) light (Schneider et al., 2008). UV phototherapy
is effective but only indicated for severely affected patients
due to the risk of skin cancer (Pathak, 1991) caused by
DNA damage. In contrast with UV, blue light is not toxic
to skin cells (Awakowicz et al., 2009). The difference in the
therapeutic effects of both spectral ranges is the result of the
interactions between these spectral ranges and their molecular
photoacceptors. UV is absorbed by DNA (Markovitsi, 2016) and
yields DNA damage (Lee et al., 2013), cell death, and remission of
psoriasis. Blue light is accepted by flavins (Eichler et al., 2005) and
porphyrins (Dai et al., 2012), resulting in a decreased proliferative
capacity and management of psoriasis. The non-toxicity and
beneficial effects of blue light make it an attractive alternative
to UV phototherapy. Emphasizing the need for establishing clear
treatment recommendations that lead to an effective therapeutic
regime using blue light.
Considering that the details of the mechanism of blue light-
based therapy for psoriasis are still not fully elucidated, it
seems suitable to use computational methods for their analysis.
Computational models have previously been used to predict
cellular behaviors (Savill, 2003; Gandolfi et al., 2011) and the
effects of ultraviolet irradiation on the skin (Weatherhead et al.,
2011; Zhang et al., 2015). This approach may contribute to the
investigation of processes occurring in the epidermis after blue
light irradiation, and extend our knowledge on the principles
of regulatory effects induced by this spectral range on the
keratinocytes dynamics.
Here, we study the blue light treatment of psoriasis using an
in silico approach. We first used the model to explore whether
a temporary decrease of keratinocytes hyper-proliferation can
explain the outcome of phototherapy with blue light. The
model accurately described the response to blue light therapy.
The simulations suggested that the observed decrease in the
keratinocytes proliferation rate is sufficient to reduce the
epidermal thickness and severity of psoriasis. However, it was
not sufficient to allow psoriatic epidermis to completely remodel
back to a healthy phenotype, regardless the treatment scheme.
Then, we analyzed the effect of length of treatment, fluence,
and intensity on the management of this inflammatory skin
condition. The model predicted that high efficacy is achieved by
treatment schemes with long duration and high fluence levels.
MATERIALS AND METHODS
To describe the management of psoriasis by blue light, we
implemented a computational model for BL irradiation of
psoriatic skin (BLISS; Figure 1). This model is defined by a
set of 12 ordinary differential equations (ODEs) describing
the time evolution of keratinocytes as they move vertically
through the layers of the epidermis while blue light is
shined upon them. BLISS was developed based on the
phenomenological observations of decreased proliferation and
increased differentiation of keratinocytes due to blue light,
particularly at a wavelength of 453 nm. In this section we describe
the general structure of the model, its implementation, and
analysis.
Computational Model
In contrast with UV, BL does not lead to cell death below fluences
of 500 Jcm−2 (Awakowicz et al., 2009). Instead, it affects the
proliferation and differentiation of the keratinocytes, which are
key processes in the model we propose. The general structure
and assumptions considered in the model regarding the kinetics
of keratinocytes in psoriasis are based on the work of Zhang
et al. (2015) for UV phototherapy of psoriasis. However, the
main difference with their model is the implementation of the
underlying mechanism by which the kinetics of the keratinocytes
are affected upon BL irradiation.
In the model (Figure 1), we represent psoriasis as a bi-stable
system and assume that keratinocytes show either a healthy or
diseased phenotype. We consider that both populations coexist
and interact within the epidermis. This assumption allows the
description of the effects induced by blue light therapy. The
set of ODEs describing the interactions between healthy and
diseased keratinocytes under the influence of blue light are
presented by Equations (1–12). This set of equations describes
the kinetics of keratinocytes at six stages of differentiation in
both their healthy (Equations 1–6) and diseased (Equations 7–
12) state, i.e., stem cells (Psch,d), transit amplifying cells (Pah,d),
growth arrested cells (Pgah,d), spinous cells (Psph,d), granular cells
(Pgch,d), corneocytes (Pcch,d). Stem cells and transit amplifying
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FIGURE 1 | Schematic description of the mechanistic model for blue light treatment of psoriasis. (A) The model considers the 4 sub-layers of the epidermis,
the 6 stages of differentiation for keratinocytes across the sub-layers. (B) BLISS accounts for the cellular processes of proliferation (γ ), differentiation (k), apoptosis (β),
and desquamation (α).
cells form the proliferative compartment of the epidermis, and
corneocytes are the end point of the differentiation process.
The ODEs account for the cellular processes of proliferation
(γh,d), differentiation (kh,d), apoptosis (βh,d), and desquamation
(αh,d). The cells in the proliferative compartment may divide
in one of three modes, i.e., produce to daughter cells equal to
the progenitor [self-proliferation (γh,d)], generate two daughter
cells where one corresponds to the next stage of differentiation
[asymmetric division (kah,d)], or induce two daughter cells where
both correspond to the next stage of differentiation [symmetric
division (ksh,d)]. The description of each parameter considered in
these equations is presented in Table 1. These parameters were
derived from one of three sources, i.e., the literature, calculated
from other model parameters as specified inTable 1, or estimated
by fitting the model to experimental data of Liebmann et al.
(2010).
dPsch
dt
=
[
γ1hθBLγ
(
1−
Psch +
Pscd
λ
Pmaxsc
)
− k1shθBLk − β1h
]
Psch + k−1h Ptah (1)
dPtah
dt
=
(
γ2hθBLγ − k2shθBLk − β2h − k−1h
)
Ptah −
(
k1ah + 2k1sh
)
θBLkPsch + k−2hPgah (2)
dPgah
dt
=
(
k2ah + k2sh
)
θBLk
Ptah −
(
k−2h + k3hθBLk + β3h
)
Pgah (3)
dPsph
dt
= k3hθBLkPgah −
(
k4hθBLk + β4h
)
Psph (4)
dPgch
dt
= k4hθBLkPsph −
(
k5hθBLk + β5h
)
Pgch (5)
dPcch
dt
= k5hθBLkPgch − ahPcch (6)
dPscd
dt
=
[
γ1dθBLγ
(
1−
Psch + Pscd
λPmaxsc
)
− k1sdθBLk − β1d
]
Pscd −
KpP
2
scd
K2a + P
2
scd
+ k−1dPtad (7)
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TABLE 1 | BLISS model parameterization.
Parameter Description Value Source
Pmaxsc Growth capacity of stem cells 4.5 × 10
3 mm−2 Zhang et al., 2015
γ1hom Minimal stem cell self-proliferation rate constant 3.30 × 10
−3 d−1 Zhang et al., 2015
k1shom Minimal symmetric healthy stem cell division rate constant 1.64 × 10
−3 d−1 Clayton et al., 2007; Zhang et al., 2015
k1ahom Minimal asymmetric healthy stem cell division rate constant 1.31 × 10
−2 d−1 Clayton et al., 2007; Zhang et al., 2015
γ2h Healthy transit amplifying cells self-proliferation rate constant 1.40 × 10
−2 d−1 Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
k2sh Healthy transit amplifying cells symmetric division rate constant 1.73 × 10
−2 d−1 Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
k2ah Healthy transit amplifying cells asymmetric division rate constant 1.38 × 10
−1 d−1 Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
k3h Healthy growth arrested to spinous cells differentiation rate constant 2.16 × 10
−1 d−1 Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
k4h Healthy spinous to granular cells differentiation rate constant 5.56 × 10
−2 d−1 Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
k5h Healthy granular cells to corneocytes differentiation rate constant 1.11 × 10
−1 d−1 Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
k−1h Back conversion rate constant of healthy cells (transit amplifying to
stem cells)
1.00 × 10−6 d−1 Zhang et al., 2015
k−2h Back conversion rate constant of healthy cells (growth arrested to
transit amplifying cells)
1.00 × 10−6 d−1 Zhang et al., 2015
ω Maximum fold increase of stem cells proliferation rate 100 Heenen et al., 1998; Zhang et al., 2015
n Stem cells proliferation rate regulation by transit amplifying cells 3 Zhang et al., 2015
AIh Epidermal apoptosis index for healthy skin 0.12% Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
β1h Apoptosis rate of healthy epidermal stem cells 1.97 × 10
−6 d−1 Calculated as described by Equation 16
β2h Apoptosis rate of healthy transit amplifying cells 2.08 × 10
−5 d−1 Calculated as described by Equation 16
β3h Apoptosis rate of healthy growth arrested cells 2.60 × 10
−4 d−1 Calculated as described by Equation 16
β4h Apoptosis rate of healthy spinous cells 6.68 × 10
−5 d−1 Calculated as described by equation 16
β5h Apoptosis rate of healthy granular cells 1.33 × 10
−4 d−1 Calculated as described by Equation 16
αh Healthy corneocytes desquamation rate constant 7.14 × 10
−2 d−1 Weinstein et al., 1985; Bauer et al., 2001;
Hoath and Leahy, 2003; Zhang et al., 2015
ρsc Fold change of stem cells proliferation in psoriasis 4 Weinstein et al., 1985; Zhang et al., 2015
ρta Fold change of transit amplifying cells proliferation in psoriasis 4 Weinstein et al., 1985; Zhang et al., 2015
ρtr Fold change of psoriatic cells transit rate 5 Weatherhead et al., 2011; Zhang et al., 2015
ρde Fold change of psoriatic corneocytes desquamation 4 Weinstein and Van Scott, 1965; Zhang et al.,
2015
λ Fold change of stem cells growth capacity in psoriasis 3.5 Heenen et al., 1987; Simonart et al., 2010;
Zhang et al., 2015
Kp Maximum immune response rate 6 Zhang et al., 2015
Ka Half-activation of immune system by psoriatic stem cells density 380 Zhang et al., 2015
γ1d Diseased stem cell self-proliferation rate constant 1.16 × 10
−2 d−1 Calculated as the product of γ1hom and ρsc
k1sd Symmetric diseased stem cell division rate constant 5.70 × 10
−3 d−1 Calculated as the product of k1shom and ρsc
k1ad Asymmetric diseased stem cell division rate constant 4.59 × 10
−2 d−1 Calculated as the product of k1shom and ρsc
γ2d Diseased transit amplifying cells self-proliferation rate constant 4.90 × 10
−2 Calculated as the product of γ2h and ρta
k2sd Diseased transit amplifying cells symmetric division rate constant 6.06 × 10
−2 d−1 Calculated as the product of k2sh and ρta
k2ad Diseased transit amplifying cells asymmetric division rate constant 4.83 × 10
−1 d−1 Calculated as the product of k2ah and ρta
k3d Diseased growth arrested to spinous cells differentiation rate constant 9.72 × 10
−1 d−1 Calculated as the product of k3h and ρtr
k4d Diseased spinous to granular cells differentiation rate constant 2.50 × 10
−1 d−1 Calculated as the product of k4h and ρtr
k5d Diseased granular cells to corneocytes differentiation rate constant 3.89 × 10
−1 d−1 Calculated as the product of k5h and ρtr
AId Epidermal apoptosis index for psoriatic skin 0.035% Bauer et al., 2001; Hoath and Leahy, 2003;
Zhang et al., 2015
β1d Apoptosis rate of diseased epidermal stem cells 2.01 × 10
−6 d−1 Calculated as described by Equation 17
β2d Apoptosis rate of diseased transit amplifying cells 2.12 × 10
−5 d−1 Calculated as described by Equation 17
(Continued)
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TABLE 1 | Continued
Parameter Description Value Source
β3d Apoptosis rate of diseased growth arrested cells 3.40 × 10
−4 d−1 Calculated as described by Equation 17
β4d Apoptosis rate of diseased spinous cells 8.76 × 10
−5 d−1 Calculated as described by Equation 17
β5d Apoptosis rate of diseased granular cells 1.36 × 10
−4 d−1 Calculated as described by Equation 17
αd Diseased corneocytes desquamation rate constant 2.50 × 10
−1 d−1 Calculated as the product of αh and ρde
aγ Blue light coefficient for proliferation factor 1 Estimated from Liebmann et al., 2010
bγ Blue light coefficient for proliferation factor −3.40 × 10
−3 Estimated from Liebmann et al., 2010
ak Blue light coefficient for differentiation factor 2.46 Estimated from Liebmann et al., 2010
bk Blue light coefficient for differentiation factor 1.94 × 10
−2 Estimated from Liebmann et al., 2010
ck Blue light coefficient for differentiation factor 3.46 Estimated from Liebmann et al., 2010
θBL β500−750 Blue light factor increasing the apoptosis rate at fluences higher than
500 Jcm−2 and lower than 750 Jcm−2
3.9 × 10−2 Awakowicz et al., 2009
θBL β>750 Blue light factor increasing the apoptosis rate at fluences higher than
750 Jcm−2
5 × 10−2 Awakowicz et al., 2009
ξabs Energy absorbance of the epidermis for a low perfused Caucasian skin 57.9% Calculated from optical model
dPtad
dt
=
(
γ2dθBLγ − k2sdθBLk − β2d − k−1d
)
Ptad
−
(
k1ad + 2k1sd
)
θBLkPscd + k−2dPgad (8)
dPgad
dt
=
(
k2ad + k2sd
)
θBLkPtad
−
(
k−2d + k3dθBLk + β3d
)
Pgad (9)
dPspd
dt
= k3dθBLkPgad −
(
k4hθBLk + β4d
)
Pspd (10)
dPgcd
dt
= 0 (11)
dPccd
dt
= k5dθBLkPgcd − adPccd (12)
Where
γ1h
γ`1,hom
=
k1ah
k1a,hom
=
k1sh
k1s,hom
=
ω
1+ (ω − 1)
(
Ptah + Ptad
Pta,hom
)n (13)
In psoriasis, the increased number of keratinocytes is the result
of a hyper-proliferative population of basal cells and a sustained
activation of the immune system. In the model, the hyper-
proliferative population is represented by the diseased stem cells
and transit amplifying cells proliferating at a rate γd, which is
faster than the proliferative rate of their healthy counterparts.
It is assumed that there are a maximum number of stem cells
Pmaxsc available in the epidermis, which limits the numbers of
healthy and diseased stem cells Psch,d. The diseased stem cells
have a larger growth capacity defined by fold increase λ. The
sustained activation of the immune system is considered through
the removal of diseased stem cells in Equation (7). The sustained
immune system response is regulated by the density of diseased
stem cells and defined by the maximum killing rate Kp and the
half activation of the immune system Ka due to psoriatic stem
cells. The immune response is ample when the cell density of
diseased cells exceeds the threshold defined by Ka.
In Equation (13), γ1,hom, k1a,hom, k1s,hom are the homeostatic
rate constants for each division process, and Pta,hom is the
homeostatic density of transit amplifying cells (Zhang et al.,
2015). The density of the total transit amplifying cells population
is the sum of the healthy and diseased groups of transit
amplifying cells. The maximum increase in the growth fraction
and decrease in the cell cycle time of fast proliferating stem
cells is indicated by ω. n represents the steepness of the stem
cells proliferation rate regulated by the transit amplifying cells
population. When the number of healthy transit amplifying cells
is low, the proliferation and division rates of the healthy stem cells
increase. Alternatively, the healthy stem cell parameter rates are
at their minimum values when the population of healthy transit
amplifying cells equals its homeostatic population. It is assumed
that psoriatic stem cells are not regulated by the population of
transit amplifying cells. Thus, they proliferate with rates ρsc fold
higher than the healthy stem cells rate constants in homeostasis.
The proliferation and differentiation rates of diseased transit
amplifying cells (γ2d, k2sd, and k2ad) are ρta fold changes higher
than the rates of healthy transit amplifying cells. Similarly the
diseased cells in the non-proliferative compartment, i.e., Pgad and
Pspd, differentiate ρtr times faster than their healthy counterparts.
The desquamation (αd) of psoriatic corneocytes is affected by ρde.
Note that Equation (11) equals to zero, given that granular cells
are lost in psoriasis due to abnormal differentiation.
Irradiation with blue light exponentially decreases the
proliferation rate of all healthy and diseased proliferative
keratinocytes by a fluence dependent factor θBLγ with a value
between 0 and 1 (Equation 14).
θBLγ = aγ e
(bγ F) with aγ > 0 and bγ < 0 (14)
Based on the keratinocytes behavior experimentally observed
(Liebmann et al., 2010), blue light might also directly affect
the differentiation rate of the keratinocytes in an exponential
manner by a fluence dependent factor θBLk with a value between
0 and 1 (Equation 15). Parameters related to the decrease of the
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proliferation and increase of differentiation rates were initially
estimated by fitting in vitro data from Liebmann et al. (2010).
θBLk = ck − ake
(bkF) with ak, bk and ck > 0 (15)
Blue light phototherapy is divided into sessions with a certain
fluence F, defined by the product of the irradiation time and the
average intensity Iav at which light is shined on the skin. The
treatment sessions can occur one time per day in a daily or spread
out basis. In the model we consider that each day of treatment
affects the proliferation of the keratinocytes, based on F >0. In
days where no treatment is provided F = 0 and θBLγ = θBLk = 1.
The apoptosis rates of the healthy keratinocytes βh (Equation
16) are determined by the differentiation rate of each population
(k1sh, k2sh, k3h, k4h, k5h) and the probability of a cell undergoing
apoptosis (apoptotic index AIh). The apoptotic index is a
common measurement for quantifying the extent of apoptosis
for a given cell population. It is defined as the ratio of apoptosis
rate to the total out flux. At fluences higher than 500 Jcm−2 BL
increases the apoptosis of keratinocytes by factor θBLβ . Thus,
accounting for the cytotoxicity observed only at high fluences of
blue light (Awakowicz et al., 2009). Below 500 Jcm−2, θBLβ has a
value of 0, for F between 500 and 750 Jcm−2 its value is 0.039, and
0.05 above 750 Jcm−2.
βh =
AIhkj
1− AIh
+ θBLβ j ∈ {1sh, 2sh, 3h, 4h, 5h} (16)
The diseased keratinocytes have an apoptosis rate defined by the
apoptotic index of psoriatic cells AId, the differentiation rate of
each population (k1sd, k2sd, k3d, k4d, k5d) and qBLβ . (Equation 17).
βd =
AIdkj
1− AId
+ θBLβ j ∈ {1sd, 2sd, 3d, 4d, 5d} (17)
The skin has specific wavelength dependent optical properties
that must be considered in the model, i.e., refractive index,
absorption coefficient, scattering coefficient, and anisotropy
factor (van Gemert et al., 1989). These properties vary per skin
layer and skin type (Zonios et al., 2001). BLISS accounts for a low
perfused type 1–3 skin with an epidermal energy absorbance level
of 57.9%. This value was computed using an unpublished five-
layered optical model developed in LightTools (Synopsis). The
energy absorbance value defines the amount of BL energy that is
absorbed by the epidermis. Skin types 4–6 have a higher energy
absorbance, however are not considered in the model.
Model Implementation and Analysis
The model was implemented in Matlab (The Mathworks Inc.).
The ODE system was solved with ode-solver ode15s. The inputs
of the model were the BL irradiation parameters (Table 2) and
the initial cell density of the 12 keratinocyte populations (Table 3)
representing an psoriatic epidermis (Simonart et al., 2010; Zhang
et al., 2015). The total keratinocytes cell density in the simulated
epidermis at t = 0 was of 217,556 cells per mm2, which is 2
times higher than that of healthy skin (∼100,000 cells per mm2;
Hoath and Leahy, 2003). BLISS is available at GitHub1 and
1https://github.com/ZFelixGarza/BLISS
TABLE 2 | Blue light irradiation parameters.
Parameter Value
Fluence 90 Jcm−2
Irradiation mode Continuous or pulsed
Irradiation time 1800 s (30 min)
Duration of treatment 84 days
TABLE 3 | Initial cell density distribution (cells per mm2).
Keratinocytes population Healthy Psoriatic
Corneocytes 185 77,633
Granular cells 119 0
Spinous cells 238 79,788
Growth arrested cells 61 20,536
Transit amplifying cells 77 32,098
Stem cells 362 6459
Total 1042 + 216514 = 217,556
the BioModels Database2 (Chelliah et al., 2015) with identifier
MODEL1701090001.
A full treatment of blue light was simulated by modifying the
proliferation, differentiation, and apoptotic rates on the day of
a BL session during the whole treatment. For example, if the
treatment sessions occurred three times per week for 8 weeks, the
rates were only varying on those specific days during the 8 weeks
of treatment. During a treatment session, light can be shined in
a continuous (CW) or pulsed (PW) mode. In CW the fluence
of blue light, defined as power density I multiplied by time t, is
provided at a constant peak power density Ip, which is equal to
the average power density Iav. In PW, the epidermis is irradiated
in short pulses at an Ip higher than Iav. The model allows for the
simulation of both modes based on a given duty cycle, fluence,
and treatment time. These inputs are used to compute the Ip
and duration of each peak and define the instants in which the
proliferation rates are decreased during the treatment time.
BLISS calculates the cell densities over time, during and
after blue light phototherapy for each healthy and diseased
keratinocyte population. The model’s results can be directly
compared to in vitro data. However, in psoriasis most clinical
data is given in terms of the psoriasis area and severity index
(PASI), or its local form, i.e., the local psoriasis severity index
(LPSI; Maari et al., 2003; Weinstabl et al., 2011; Pfaff et al., 2015).
PASI is a quantitative rating score for measuring the severity of
a psoriatic lesion based on the degree of erythema, scaling and
induration per anatomic area, i.e., head, trunk, upper, and lower
limbs. Each of the three characteristics is graded on a scale from
0 to 4, giving a maximum score of 12 per area based on the
percentage of coverage. The maximum PASI is 72, mild psoriasis
which is the target of blue light treatment corresponds to a PASI
of 0–10. Induration is related to the thickness of the epidermis,
and scaliness is related to the status of the Stratum Corneum.
2http://www.ebi.ac.uk/biomodels-main/
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Both features are comprised within the model. Thus, assuming
an initial LPSI value and a positive correlation between thickness
and scaliness with the cell density of keratinocytes, the LPSI
is derived from the relative change in the total cell density of
keratinocytes as indicated by Equation (18). A similar approach
has been previously described in the literature (Ng et al., 2005;
Zhou et al., 2010).
LPSIi = LPSI0 − LPSI0
(
PToti − PTot0
PTot0
)
where i ≥ 1 (18)
Data from the clinical investigation of Pfaff et al. (2015) was used
to verify the adequate description of BL treatment of psoriasis by
the model.
Multiple Parameter Sensitivity Analysis
Amultiple parameter sensitivity analysis (MPSA) was performed
to understand how the system may be affected by uncertainty
in the model’s parameters. An initial simulation for blue light
treatment was executed with the nominal model parameters θref
presented in Table 1. From this first simulation the reference
output response yref (k) was computed, where k represents the
cell density of each keratinocyte cell densities derived by the
model. 500,000 random parameter value sets were generated with
the lhsdesign MATLAB function. The parameter sets θ(i) were
used as input to the model and simulations were implemented.
The cost function v(i) for the simulation results obtained with
each parameter set was calculated as the sum of squared errors
between the perturbed ysim and reference output yref (Equation
19).
v (i) =
∑N
k= 1
(
yref
(
k
)
− ysim
(
k, θ(i)
))2
(19)
The parameter sets were then classified as acceptable or
unacceptable and the cumulative frequency functions were
computed for the acceptable and unacceptable values of
each parameter. Then, the Kolmogorov–Smirnov statistic was
calculated as the separation between Sa(θ ) and Su(θ ) (Equation
20).
D = max
∣∣Sa(θ)− Sq(θ)∣∣ (20)
Finally, this value was used to derive the sensitivity of each
parameter on the cell density of all keratinocyte populations
at each of the six differentiation states and the local psoriasis
severity index. Additionally, a local sensitivity analysis (LPSA;
Marino et al., 2008) was performed for the parameters
identified by the MPSA for further understanding of how small
perturbations in these parameters reflect on the output of the
model.
RESULTS
The Regulation of the Keratinocytes
Proliferation Is Key in the Mechanism of
Blue Light Irradiation
Given the phenomenological observations reported in the
literature and the flexibility offered by the model to describe
them, we first analyzed all the possible in silico representations
of the changes induced on the proliferation and differentiation
of the keratinocytes. Table 4 presents a summary of all potential
cases.
The general set of ODEs used in this analysis is presented
by (Equations 1–17). Note that for cases where only θBLγ is
considered, θBLk is equal to 1. Similarly when only θBLk is
considered, θBLγ equals 1. For cases where only the stem cells and
transit amplifying cells are affected, θBLk for the differentiation
rates of growth arrested, spinous, and granular cells equals 1. For
each case, the time evolution of proliferation and differentiation
parameters, the net proliferative and differentiation capacity of
the keratinocytes, and the regulatory capacity of the immune
system is computed (Figure 2). From this analysis, it is clear
that shifting only parameters related to the symmetric and
asymmetric division of proliferative keratinocytes does not yield
a decrease on the proliferative compartment (Figures 2B,D,E).
Further, changing the division parameters causes a marked
increase in the differentiation rates (Figures 2B–D,F, H–M),
which is reflected in an increased cell density of the transit
amplifying cells in the proliferative compartment and all cells
in the non-proliferative compartment. Modifying the self-
proliferation rate of the proliferative keratinocytes leads to a
decrease on the proliferation and increase on the differentiation
of the cells in the proliferative compartment, without unrealistic
surge of the keratinocytes differentiation capacity (Figure 2A).
Thus, we conclude that the effect of blue light is best described
in silico when θBLγ is lower than 1 and θBLk is equal to 1. The
simulations and results presented in the following sections of this
work are based on this conclusion.
A Transient Decrease in the Proliferative
Capacity of Keratinocytes Lowers the
Severity of Psoriatic Lesions
The results from Section The Regulation of the Keratinocytes
Proliferation is Key in the Mechanism of Blue Light Irradiation
suggested that the experimental observations for keratinocytes
(Liebmann et al., 2010) are best described by the model when the
self-proliferation rate of all stem cells and transit amplifying cells
decreases during blue light irradiation. Simulations performed
for the same conditions of that in vitro study show a similar
reduction in the relative cell number achieved after BL irradiation
at fluence of 33, 66, and 100 Jcm−2 (Figure 3A). To verify
that the model was also able to describe the reduced severity
achieved by blue light treatment of psoriatic skin, simulations
(Figure 3B) were performed and compared to data from the
clinical investigation of Pfaff et al. (2015). Their clinical study
measured the LPSI of psoriatic patients after irradiating the skin
with 90 Jcm−2 of pulsed blue light for 12 weeks at either a
low (LI), 100 mWcm−2, or high (HI), 200 mWcm−2, peak
intensities. During the first 4 weeks the patients were treated
every day, the next 8 weeks the therapy occurred three times
per week. In the simulations, the initial LPSI values are equal
to those of the clinical investigation (Pfaff et al., 2015; i.e.,
5.52 for LI and 5.17 for HI). The model achieved an accurate
representation of the applied treatments at low and high peak
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TABLE 4 | Possible cases describing the blue light effects on the cellular processes of keratinocytes.
Case Rate modified Value of blue light factors θBLγ and θBLk Population affected
1 Self-proliferation rates γ1 and γ2 are decreased. θBLγ < 1 and θBLk = 1 for proliferative cells Proliferative cells, i.e. stem cells and
2 Asymmetric (k1a and k2a) and symmetric (k1s and k2s)
division rates of proliferative cells are increased.
θBLγ = 1 and θBLk > 1 for proliferative cells transit amplifying cells.
3 The self-proliferation rates (γ1 and γ2) are decreased and
the asymmetric and symmetric division rates (k1a, k2a,
k1s, and k2s) are increased.
θBLγ <1 and θBLk > 1 for proliferative cells
4 Asymmetric (k1a and k2a) division rates are increased. θBLγ =1 and θBLk > 1 (for the asymmetric
division rates of proliferative cells)
5 Symmetric (k1s and k2s) division rates are increased. θBLγ = 1 and θBLk > 1 (for the symmetric
division rates of proliferative cells)
6 The self-proliferation rates (γ1 and γ2) are decreased and
the asymmetric division rates (k1a and k2a) are increased.
θBLγ < 1 and θBLk > 1 (for the asymmetric
division rates of proliferative cells)
7 The self-proliferation rates (γ1 and γ2) are decreased and
the symmetric division rates (k1s and k2s) are increased.
θBLγ < 1 and θBLk > 1 (for the symmetric
division rates of proliferative cells)
8 Differentiation rates (k3, k4, and k5) of non-proliferative
cells are increased.
θBLγ = 1 and θBLk > 1 (for division rates of
non-proliferative cells)
Non-proliferative cells, i.e. growth arrested
cells, spinous cells, and granular cells.
9 Differentiation rates (k1a, k1s, k2a, k2s, k3, k4, and k5) of
all cells are increased.
θBLγ = 1 and θBLk > 1 (for division rates of
all cells)
Proliferative cells, i.e. stem cells and transit
amplifying cells. Non-proliferative
10 The self-proliferation rates (γ1 and γ2) are decreased and
the differentiation rates (k3, k4, and k5) of
non-proliferative cells are increased.
θBLγ < 1 and θBLk > 1 (for division rates of
non-proliferative cells)
cells, i.e. growth arrested cells, spinous
cells, and granular cells.
11 The asymmetric division and differentiation rates (k1a,
k2a, k3, k4, and k5) are increased.
θBLγ = 1 and θBLk > 1 (for the asymmetric
division rates of proliferative cells and the
division rates of non-proliferative cells)
12 The symmetric division and differentiation rates (k1s, k2s,
k3, k4, and k5) are increased.
θBLγ = 1 and θBLk > 1 (for the symmetric
division rates of proliferative cells and the
division rates of non-proliferative cells)
13 The self-proliferation rates (γ1 and γ2) are decreased and
the division and differentiation rates (k1a, k1s, k2a, k2s,
k3, k4, and k5) are increased.
θBLγ > 1 and θBLk > 1 (for division rates of
all cells)
intensities, particularly during the first 4 weeks. In the next 8
weeks, the in silico results are less pronounced compared to the
clinical study. The final values predicted by the model are within
the error margins of the experimental results. Based on the results
of the simulations performed for the experimental and clinical
studies, it is evident that the transient decrease in proliferation
has a pivotal role in the underlying mechanism of blue light
treatment.
To assess the impact of changes in the proliferation rate
and other model parameters on the outcome of the treatment,
a multiple parameter sensitivity analysis was implemented.
Figure 4 presents the results of this analysis for all model
parameters in relation to the keratinocyte cell densities
(Figure 4A) and the LPSI (Figure 4B). According to Figure 4A,
the model output is mainly affected by 12 parameters related
to the proliferation of stem cells and transit amplifying cells.
However, not all keratinocyte populations are evenly altered
by variations in these parameters, some affect only the healthy
populations while others have an impact on the diseased
populations. The cell density of psoriatic keratinocytes is mainly
affected by the proliferation rate of healthy and diseased transit
amplifying cells. Conversely, the proliferation rate of psoriatic
stem cells only impacts the healthy populations and the psoriatic
stem cells. The LPSA performed for these 12 sensitive parameters
indicated that diseased transit amplifying cells are most sensitive
to small perturbations on the proliferation rate of healthy transit
amplifying cells. This parameter as well as the proliferation rate
of diseased stem cells and transit amplifying cells are directly
related to the fluence, intensity and irradiation time used by
the implemented treatment. From the 12 parameters identified
in the MPSA for keratinocytes cell density, only seven have
a strong impact on the local severity of psoriasis at the end
of treatment (Figure 4B). These seven parameters correspond
to those affecting the cell densities of diseased keratinocyte
populations. The impact of these parameters on the LPSI
is consistent with the effect on the cell density of diseased
keratinocytes, but lower in comparison to the latter.
Based on the sensitivity analysis, it was confirmed that
the decreased proliferation capacity induced by blue light
irradiation directly impacts all keratinocytes populations. Despite
the insightful information this analysis provided, it was yet
unclear how each keratinocyte population varied before, during,
and after shining blue light on the skin. Thus, a simulation
(Figure 5) was executed for the blue light treatment of a lesional
skin area of 1 mm2 for 84 days, using a fluence of 90 Jcm−2.
The simulated scheme was divided into two sections, the first one
with everyday treatment, and the second one with three times
per week irradiations. The time evolution of both healthy and
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FIGURE 2 | Representing in silico the blue light effect by decreasing the proliferation rate of keratinocytes yields the behavior observed
experimentally. The panels show the changes on the proliferation and differentiation of healthy and diseased keratinocytes due to different approaches of blue light in
silico representation. Thirteen different cases are depicted in this figure. A detailed description of each case can be found in Table 4. These cases are grouped
according to the parameters affected by blue light. Panels (A–G) show cases where only the proliferation and division parameters from the proliferative compartment
are modified during blue light irradiation. Panel (H) presents the case where only the differentiation parameters from the non-proliferative compartment are affected.
Panels (I–M) described the cases where blue light irradiation impacts both compartments. The upper plots of each panel show the impact of the blue light factor on
the proliferation and differentiation rates of all keratinocyte populations as a consequence of the parameters affected by blue light. The lower panels display the impact
of each potential representation on the proliferative (green), differentiation (blue), and immune system-cytotoxic (red) capacities.
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FIGURE 3 | BLISS accurately describes in vitro and in vivo data. (A) The relative keratinocyte density is computed (solid black line) for irradiation schemes with
fluences between 0 and 100 Jcm−2 and compared to the experimental data (Liebmann et al., 2010) of keratinocytes irradiated with three fluences of continuous wave
blue light (gray dot). (B) The changes in the severity of a psoriasis lesion during (blue bar) and after treatment (black bar) are predicted (solid lines) for a pulsed wave
treatment at high (red) and low (blue) intensities. These changes in the severity of the disease are shown in terms of the local psoriasis severity index (LPSI). The in
silico results are compared to the clinical data (dots) of Pfaff et al. (2015).
diseased keratinocytes is depicted in Figures 5A,B respectively.
The model predicted that the cell density of all keratinocyte
populations decreases due to the repetitive irradiation with
blue light. However, the cell density of diseased keratinocytes
remained considerably high after the treatment compared to
the cell density of healthy keratinocytes. Thus, no shift to a
healthy phenotype was achieved by this therapeutic approach.
The model suggested that a lesional state may prevail after the
treatment, but some improvements might be observed within
the period of phototherapy. Additionally, it predicted that a less
pronounced decrease in the cell density of all keratinocytes is
achieved when the treatment occurs every other day compared
to daily treatment. This observation suggests that the longer the
period of daily treatment the lower the final LPSI value.
Blue Light Treatment Schemes with Long
Duration and High Fluence Yield High
Efficacy in the Management of Psoriasis
Hitherto, the model predicted that regulating the hyper-
proliferative populations of keratinocytes induces a transient
management of psoriasis. However, it also showed that the
treatment scheme used in the simulations has a direct impact
in the predicted outcome. This observation agrees with the
large variations perceived in the results from the available
clinical investigations (Maari et al., 2003; Weinstabl et al., 2011;
Kleinpenning et al., 2012; Pfaff et al., 2015). Therefore, we studied
the impact of each treatment parameter on the efficacy of the
therapeutic approach. Figure 5B shows a prominent decrease
in the cell densities of diseased keratinocytes when the blue
light is constantly shinned upon the skin compared to when the
irradiation is less frequent. To further analyze this observation,
simulations were executed for therapy schemes with a total
duration of 4–28 weeks, using either a daily or every other
day treatment (Figure 6A). The results showed that the longer
the period of daily treatment the lower the final LPSI value.
Nevertheless, the relative change in the LPSI value decreased for
treatment periods longer than 20 weeks. Further, BLISS predicted
that for a blue light phototherapy scheme where both daily and
every other day treatment sessions are used, higher efficacy is
achieved with an increasing number of daily treatment sessions.
Given that repeated treatment sessions seemed to yield
higher efficacy, we then tested whether the same trend applied
to the irradiation mode of treatment scheme. As previously
mentioned a given fluence of blue light can be shinned on
the skin in either a continuous or pulsed mode. Both cases
comprise the same average intensity, however the peak intensity
differs. Pfaff et al. studied in vivo the impact of low and
high peak intensities in the pulsed irradiation of psoriatic skin
(Pfaff et al., 2015). They observed minor differences between
low and high peak intensity groups; however this trend was
not seen in silico (Figure 3B solid lines vs. dots). In the
model, both low and high intensity pulsed treatment led to
the same trend. These results led to questioning whether the
model could predict a different outcome for treatment strategies
with pulsed and continuous irradiation. Thus, simulations were
implemented for low and high power densities in pulsed and
continuous modes (Figures 6B–D), considering a 12 weeks
treatment and 4 weeks follow-up with an average fluence
of 90 Jcm−2 and an average intensity of 50 mWcm−2 for
both irradiation modes. Figure 6B compares the efficacy of
pulsed and continuous mode in terms of the local psoriasis
severity index. In the simulations for the pulsed mode, low
(100 mWcm−2) and high (200mWcm−2) peak intensities were
used. No differences were observed between both modes, or
between low and high peak power densities. Hence, the model
suggested that duration rather than intensity determines the
efficacy of the treatment. This prediction was further tested by
simulating the treatment of a psoriatic epidermis using power
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FIGURE 4 | Multiple parameter sensitivity shows that variations in the proliferation parameters have a high impact on the final keratinocyte cell
densities and the local severity of psoriasis at the end of treatment. (A) The sensitivity of healthy and diseased keratinocytes (x axis) to variations in the 58
model parameters (y axis) is depicted in the heat map. Only those with a Kolmogorov–Smirnov statistic value higher than 0.3 are shown in the y axis. (B) The
sensitivity of the treatment outcome to changes in the same model parameters of Panel (A) are shown in the bar plot in terms of the local psoriasis severity index. Only
those parameters with a Kolmogorov-Smirnov statistic value higher than 0.3 are shown in the x axis.
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FIGURE 5 | Blue light induces a temporary reduction of all keratinocyte populations during the length of the treatment. (A) The time evolution of the
healthy keratinocyte cell densities (dashed lines) comprised in a psoriatic epidermis are described during (blue bar) and after (black bar) blue light-based therapy. (B)
Similarly, the time evolution of the diseased keratinocytes (continuous lines) is shown during and after treatment. Note the difference in scales of the y-axes between
panels (A) and (B). In this simulation, the treatment periods divided into two sections. The first one consists of 28 days, with irradiation sessions occurring every day.
The second section comprises 56 days, with treatment sessions happening three times per week. On each session a fluence of 90 Jcm−2 is applied for 30 min.
densities of 100, 200, and 600 mWcm−2 in the continuous mode
(Figures 6C,D).
In addition to time and intensity, fluence is another important
parameter of the treatment scheme. Simulations performed for
fluences between 0 and 750 Jcm−2, considering a treatment of
12 weeks (Figure 7A) predicted that fluence levels as low as
45 Jcm−2 lead to a decrease in the LPSI value. Moreover, at
fluence levels between 200 and 500 Jcm−2 a saturation point
was observed. At fluences equal or higher than 500 Jcm−2 the
decrease in the LPSI value was considerably larger due to the
cytotoxicity induced by BL at these levels. According to these
results, low fluences would lead to a minor decrease in the
LPSI compared to higher fluences. This observation is better
understood when analyzing the relation between the fluence,
the blue light factor θBLγ , and the consequent proliferation rate
derived by the model (Figure 7B). Here, we show only the
analysis for the proliferation rate of diseased transit amplifying
cells, but the trends are consistent for the other proliferative
populations. A clear exponential decrease is seen on both the blue
light factor and the proliferation rate with increasing fluences.
However, the impact of fluence on the proliferation rate is steeper
and faster compared to the effect on the blue light factor. Further,
for fluences below 500 Jcm−2 both the blue light factor and the
proliferation rate are reduce in an almost linear manner. But it
is less abrupt at fluences above 200 Jcm−2. The fluence effect
translates into a linear reduction of the proliferation in relation
to the blue light factor, which yields a lower cell density and
the consequent improvement on the psoriatic skin. The model
was designed to allow bi-stability at either a diseased or healthy
phenotype. The healthy state can only be reached when the total
cell density at the end of treatment is dominated by healthy
keratinocyte populations. To achieve the switch in the ruling type
of population, the number of diseased cells must be considerably
lowered during the treatment. Our results showed that this shift
in phenotypes could not be acquired with blue light fluences
where no cytotoxicity was induced (Figures 7C,D). Figure 7C
presents the relation between healthy and diseased stem cells
with increasing fluence levels. From this figure is clear that only
fluences above 500 Jcm-2 achieve a majority of healthy stem cells.
Fluences below that level reduce the cell densities but remain
within the diseased state due to a high predominance of diseased
keratinocytes (Figure 7D).
DISCUSSION
Blue light at 420 and 453 nm is highly effective in the
management of psoriasis (Weinstabl et al., 2011; Pfaff et al.,
2015) without any adverse effects (Awakowicz et al., 2009;
Kleinpenning et al., 2010). We have explored the underlying
mechanism of this therapeutic method and the impact of
the treatment scheme on the efficacy of the treatment using
an in silico approach. BLISS suggests that the decrease in
the keratinocytes proliferative capacity is sufficient to induce
a transient decrease in the severity of psoriasis. Further,
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FIGURE 6 | The length of treatment is a key factor to achieve high treatment efficacy. (A) The LPSI at the end of treatment is predicted for treatment protocols
with a total duration of 4–28 weeks. The treatment sessions in the simulated protocols occur either on a daily (blue dots) or every other day (green dots) basis. (B) A
12 weeks treatment with fluence of 90 Jcm−2 is simulated for continuous (black) and pulsed irradiation with low (blue) and high (red) peak intensities. (C) The variation
in the LPSI value is predicted for irradiation schemes with low and high intensities of continuous wave blue light. (D) The evolution of the total keratinocyte cell
densities during (blue bar) and after (black bar) treatment are derived using the same low and high intensities of continuous wave blue light presented in panel (C).
it predicts that treatment schemes with long duration and
high fluence yield the most optimal outcome. The model
constitutes a fast and flexible tool that considers not only
the properties of the irradiated epidermis but also the
interactions between the structural cells within it. Our in
silico method provides a framework for further insight on the
underlying mechanism of this blue light-based phototherapy
and the optimal treatment of psoriasis. To the extent of our
knowledge, this is the first model that studies the changes
induced by blue light irradiation on the cell dynamics of
keratinocytes. The general concepts of epidermal kinetics used
here have been applied to UV phototherapy (Grabe and Neuber,
2007; Weatherhead et al., 2011; Zhang et al., 2015) before.
Nevertheless, the differences on the underlying mechanism
make the previous models and ours two utterly different
applications.
On this work, we first addressed how to best represent
these phenomenological observations in silico while accounting
for the characteristic phenotype of psoriasis (Perera et al.,
2012). From experimental studies, it is known that blue light
decreases the proliferative capacity of keratinocytes and other
cell types (Taoufik et al., 2008; Wataha et al., 2008), and that
it reduces their proliferation by inducing their differentiation
(Liebmann et al., 2010). However, it is not clear how exactly these
changes are exerted on the cellular processes of keratinocytes.
BLISS accounts for the three main theories of cell division
(Clayton et al., 2007; Klein et al., 2011; Watt, 2014), i.e.,
self-proliferation, asymmetric, and symmetric division. Self-
proliferation refers to the ability of a cell dividing into two
daughter cells of the same kind. Asymmetric division considers
that one proliferative cell divides intro one daughter cell of the
same kind and one of the next differentiation stage. Finally,
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FIGURE 7 | High fluences of blue light yield higher management of psoriasis than low fluences. (A) The LPSI over time is computed for a 12 weeks
continuous wave treatment with an initial LPSI of 5.17 (Pfaff et al., 2015) using 11 fluences. (B) The behavior of the blue light factor θBLγ and the proliferation rate are
visualized as functions of the fluence. (C) The bi-stability of the model is evaluated in the logarithmic scale for a wide range of fluences in a phase diagram of healthy
and diseased keratinocytes. Only fluences above 500 Jcm−2 yield a shift the dominant keratinocyte population and the phenotype of the skin. (D) Fluences below this
level remain in the disease state.
symmetric division comprises the division of a proliferative
cell into two cells of the next differentiation stage. In the
model the proliferation and differentiation of keratinocytes
in the proliferative compartment is represented by their self-
proliferation, symmetric, and asymmetric division parameters.
The keen reader could think that in order to best describe
the effect of blue light on proliferation and differentiation,
increasing the rates of asymmetric and symmetric division
should be enough to achieve similar observations as those
reported in vitro. Alternatively, the direct increase on the
division rates of proliferative cells should be coupled to the
decrease of the self-proliferation rate of all keratinocytes in
the proliferative compartment. Thus, capturing the increase in
differentiation and the decrease in proliferation of the irradiated
keratinocytes. Our analysis (Figure 2) showed that modifying
the division rates alone does not appropriately reflect on the
proliferative capacity of the cells. Additionally, it translates
into high peaks in the cell density of transit amplifying and
non-proliferative cells, which are biologically unlikely. However,
decreasing only the proliferation rate does yield the effect on
the differentiation and proliferative capacity of keratinocytes
observed experimentally. The outcome of this approach is a
transient decline in the proliferative rates of the cells and
consequent higher differentiation, translated into a temporary
drop local severity of the disease. BLISS comprises a fine tuning
between the proliferation and division rates of all keratinocytes,
particularly of healthy stem cells. It considers a strong connection
between the proliferation and division rates of healthy stem
cells and their regulation by the total population of healthy
and diseased transit amplifying cells. This fact might explain
the outcome of our analysis. From the sensitivity analysis
(Figure 4), it was clear that proliferation-related parameters
had the highest influence on the final cell densities and the
improvement of psoriasis due to blue light treatment. The
most sensitive parameters were directly related to the treatment
scheme. Their impact was reflected on the cell density of diseased
keratinocyte populations and local psoriasis severity index. These
observations may explain the large variations observed among
clinical investigations of BL treatment (Maari et al., 2003;
Weinstabl et al., 2011; Pfaff et al., 2015).
Previous models of phototherapy, particularly UV-based
approaches represented the therapeutic effect by inducing strong
apoptosis on the keratinocytes (Weatherhead et al., 2013; Zhang
et al., 2015). This temporal increase in the apoptotic rate leads
to a remission phase, characterized by a lower total cell density
after the treatment compared to the initial one. In our model,
apoptosis is only affected at fluences above 500 Jcm−2, instead
the proliferation and differentiation capacity of keratinocytes are
altered during the treatment sessions. The key difference in the
approaches of representing UV and BL phototherapy in silico
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is defined by the difference in the underlying mechanisms of
both therapeutic approaches. Despite both methods affecting the
cells behavior by absorption of light at a certain wavelength,
the photo-acceptors and consequent events differ. UV is mainly
absorbed by the cell’s DNA (Benedix et al., 2005), consequently
inducing direct DNA damage, apoptosis (Weatherhead et al.,
2011), and a decrease in the total cell density of the lesional skin.
Blue light irradiation does not induce DNA damage (Awakowicz
et al., 2009), it is absorbed by other photo-acceptors in the cell,
e.g., flavins (Sadeghian et al., 2008) and cryptochromes (Bouly
et al., 2007). The consequent effect is the release of nitric oxide
(Opländer et al., 2013) and reactive oxygen species (Yoshida et al.,
2013), which alter the cell’s proliferation and differentiation rates.
Clinically, this transient effect on the keratinocytes
proliferation and differentiation is observed as the improvement
of a psoriatic lesion (Weinstabl et al., 2011; Kleinpenning et al.,
2012). The model is bi-stable, thus it can reproduce steady
states for both healthy and diseased skin phenotypes. In our
simulations, we account for mild psoriasis through a specific
set of initial cell densities and show that although the plaque
is controlled during the treatment the underlying state is still
diseased. After the treatment, the model eventually goes back
to the initial diseased state. In the UV phototherapy model of
Zhang et al. (2015), they demonstrate that UV treatment with
consecutive episodes can theoretically control the disease and
achieve a remission of the psoriatic phenotype. In our model,
we do not observed this remission phase for mild psoriasis
considered with fluences below 500 Jcm−2.The lack of remission
phase in our simulations for blue light treatment in contrast with
UV phototherapy may be due to the underlying mechanism.
Increasing the apoptosis of keratinocytes yields a lower cell
density regardless of their proliferation and differentiation
rate. This effect results in a shift of the stem cell density from
the disease state to the healthy state (Figure 7C). Altering
the proliferation and differentiation rates of the proliferative
keratinocytes due to blue light irradiation only impacts their
apoptosis rates at high fluence levels. Thus, the effect of blue
light is mild compared to that of UV (Weatherhead et al., 2013).
Nevertheless, it is possible that other factors are involved in the
underlying mechanism of blue light management of psoriasis.
The inclusion of these factors in the model could potentially
yield to the shift in phenotypes and full remission of psoriatic
skin. In our method, the immune system regulates the dynamics
of the keratinocytes through the removal of disease stem cells
at a rate defined by the maximum immune killing rate and the
half activation of the immune system (Equation 7). Blue light
also induces apoptosis of T-cells (Liebmann et al., 2010; Oh
et al., 2016), alter the immune response (Fischer et al., 2013)
and decrease inflammation (Shnitkind et al., 2006). However,
the impact of BL on the immune system is not considered in
the current model. The inclusion of blue light related effects
on the immune system might result in lower keratinocyte
cell densities and the consequent shift in the phenotype. The
available clinical investigations have not assessed yet the impact
of blue light on the immune system in the context of psoriasis.
Data from skin biopsies, experimental, and clinical studies on
blue light irradiation is needed to determine which aspects
could be involved and how they should be included in the
model.
BLISS explicitly includes relevant treatment parameters, i.e.,
fluence, time, intensity, and mode of irradiation. This feature
of the model allows us to investigate the influence of these
parameters on the management of psoriasis. Recent experimental
studies have explored the effect of various wavelengths on the
blue range of the electromagnetic spectrum (Liebmann et al.,
2010; Opländer et al., 2013), and fluence on various cell types
(Awakowicz et al., 2009; Liebmann et al., 2010; Sparsa et al.,
2010; Monfrecola et al., 2014). Clinically, the limited number of
available studies focuses on the assessment of treatment efficacy
with a specific combination of parameters. Only two studies
implements a wavelength comparison (Weinstabl et al., 2011;
Kleinpenning et al., 2012), and another evaluates high and low
pulsed intensities (Pfaff et al., 2015). Nevertheless, no global
guidelines for treatment have been defined. Furthermore, the
impact on the kinetics of the main cells involved in psoriasis and
their role on themanagement of the disease are yet to be resolved.
One of the objectives of this study was to study the impact
of treatment parameters on the blue light mediated regulation
of keratinocytes in psoriasis and the consequent control of the
lesion. Our results suggested that therapy length and the applied
fluence rather than intensity of irradiation may potentially
determine the efficacy of the treatment. Simulations for various
treatment lengths (Figure 6A) showed that algorithms with a
long treatment period and consecutive episodes may be the most
effective for psoriasis. This observation could partially explain
the higher improvement of Pv symptoms achieved by Pfaff
et al. (2015) (12 weeks) in contrast with prior investigations
(4 weeks; Maari et al., 2003; Weinstabl et al., 2011). Another
reason could be the different fluences used in these studies
[10 Jcm−2 (Maari et al., 2003) and 90 Jcm−2 (Weinstabl et al.,
2011; Pfaff et al., 2015)], given the fluence dependency associated
with blue light irradiation (Liebmann et al., 2010; Dai et al.,
2012). Simulations implemented for a wide range of fluences
(Figure 7) show a negative correlation between fluence and final
LPSI value. However, no threshold value has yet been defined. To
define this value additional in vitro and in vivo data are needed.
Research on light therapy for different applications has indicated
that pulsed light is more effective than continuous light, while
others report no effect, or a worsening effect of pulsed irradiation
compared to no treatment (Lapchak et al., 2007; Hashmi et al.,
2010). In Psoriasis, only one clinical investigation has used a
pulsed irradiation mode (Pfaff et al., 2015), while the others
employed the continuous mode (Maari et al., 2003; Weinstabl
et al., 2011; Kleinpenning et al., 2012). Simulations performed
with the model (Figure 6B) indicated that pulsed light is as
effective as continuous light in the treatment of psoriasis.
The current model has some addressable limitations: (i)
it does not explicitly comprise the photo-activated processes
leading to the cellular regulation and management of psoriasis.
(ii) We neglected the additional cytotoxicity induced on the
keratinocytes at wavelengths shorter than 453 nm (Liebmann
et al., 2010). The model was built assuming irradiation at
453 nm, which is the most common wavelength used for
psoriasis (Weinstabl et al., 2011; Pfaff et al., 2015). Despite
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the minimum differences in treatment efficacy reported in the
literature (Kleinpenning et al., 2010; Weinstabl et al., 2011),
inclusion of this effect could be worth a thorough analysis.
However, additional data is needed on the optical parameters and
the skin before this feature can be included in the model.
One definite experimental test of our model should aim
at simultaneously tracing psoriasis and healthy proliferative
and non-proliferative keratinocytes to verify whether blue light
equally affects healthy and diseased proliferative cells. One
potential approach to test this hypothesis could be isolating
keratinocytes from psoriatic skin (Aasen and Belmonte, 2010)
after shinning blue light on it. In this work, we provide general
insights and recommendations based on the model results. In
the future, more precise recommendations could be derived from
the model by implementing an optimization analysis for the
treatment (Kessel et al., 2013). Our results showed that length of
treatment is vital in decreasing the severity of a psoriasis lesion,
however there is little information reported in the literature on
the direct effect of irradiation length and cumulative exposure
of cells to blue light. Future studies should explore this theory
experimentally to define the boundaries of the cellular response
and the most optimal outcome. Also, they should assess the long
term management of psoriasis and the recurrence of the lesions.
CONCLUSIONS
Overall, this study demonstrates that regulation of the
proliferative capacity of keratinocytes is a crucial process in
the blue light induced management of psoriasis. Considering
the uprising interest in blue light as treatment for inflammatory
skin conditions, the availability of irradiation guidelines becomes
of great relevance. Our model constitutes a flexible tool for
studying the underlying mechanism, formulating valuable
recommendations, and designing effective therapeutic regimes
with BL in a constraint-free environment.
AUTHOR CONTRIBUTIONS
Wrote the paper: ZCFG. Conceived and designed the
computational framework: ZCFG, JL, MB, PAJH, NAWvR.
Developed the model: ZCFG. Performed the computational
analysis: ZCFG. Revised the paper: JL, MB, PAJH, NAWvR.
Supervised the study: JL, MB, PAJH, NAWvR.
FUNDING
This project was funded under the public-private partnership
between Philips and the Eindhoven University of Technology.
ACKNOWLEDGMENTS
We are grateful to Elvira Paulussen for her contribution
to the inclusion of optical parameters in the model. The
model described here was deposited in the online repository
BioModels Database (Chelliah et al., 2015) with identifier
MODEL1701090001.
REFERENCES
Aasen, T., and Belmonte, J. C. I. (2010). Isolation and cultivation of human
keratinocytes from skin or plucked hair for the generation of induced
pluripotent stem cells. Nat. Protoc. 5, 371–382. doi: 10.1038/nprot.2009.241
Awakowicz, P., Bibinov, N., Born, M., Busse, B., Gesche, R., Helmke,
A., et al. (2009). Biological stimulation of the human skin applying
healthpromoting light and plasma sources. Contrib. Plasma Phys. 49, 641–647.
doi: 10.1002/ctpp.200910068
Bauer, J., Bahmer, F. A., Wörl, J., Neuhuber, W., Schuler, G., and Fartasch, M.
(2001). A strikingly constant ratio exists between Langerhans cells and other
epidermal cells in human skin. A stereologic study using the optical disector
method and the confocal laser scanning microscope. J. Invest. Dermatol. 116,
313–318. doi: 10.1046/j.1523-1747.2001.01247.x
Benedix, F., Berneburg, M., and Röcken, M. (2005). Phototherapy with
narrowband vs broadband UVB. Acta Derm. Venereol. 85, 98–108.
doi: 10.1080/00015550510025579
Bouly, J.-P., Schleicher, E., Dionisio-Sese, M., Vandenbussche, F., VanDer Straeten,
D., Bakrim, N., et al. (2007). Cryptochrome blue light photoreceptors are
activated through interconversion of flavin redox states. J. Biol. Chem. 282,
9383–9391. doi: 10.1074/jbc.M609842200
Chelliah, V., Juty, N., Ajmera, I., Ali, R., Dumousseau, M., Glont, M., et al.
(2015). BioModels: ten-year anniversary. Nucleic Acids Res. 43, D542–D548.
doi: 10.1093/nar/gku1181
Clayton, E., Doupé, D. P., Klein, A. M., Winton, D. J., Simons, B. D., and Jones, P.
H. (2007). A single type of progenitor cell maintains normal epidermis. Nature
446, 185–189. doi: 10.1038/nature05574
Dai, T., Gupta, A., Murray, C. K., Vrahas, M. S., Tegos, G. P., and
Hamblin, M. R. (2012). Blue light for infectious diseases: propionibacterium
acnes, Helicobacter pylori, and beyond? Drug Resist. Updat. 15, 223–236.
doi: 10.1016/j.drup.2012.07.001
Eichler, M., Lavi, R., Shainberg, A., and Lubart, R. (2005). Flavins are source
of visible-light-induced free radical formation in cells. Lasers Surg. Med. 37,
314–319. doi: 10.1002/lsm.20239
Fischer, M. R., Abel, M., Lopez Kostka, S., Rudolph, B., Becker, D., and von Stebut,
E. (2013). Blue light irradiation suppresses dendritic cells activation in vitro.
Exp. Dermatol. 22, 558–560. doi: 10.1111/exd.12193
Gandolfi, A., Iannelli, M., and Marinoschi, G. (2011). An age-structured model of
epidermis growth. J. Math. Biol. 62, 111–141. doi: 10.1007/s00285-010-0330-3
Grabe, N., and Neuber, K. (2007). Simulating psoriasis by
altering transit amplifying cells. Bioinformatics 23, 1309–1312.
doi: 10.1093/bioinformatics/btm042
Hashmi, J. T., Huang, Y.-Y., Sharma, S. K., Kurup, D. B., De Taboada, L., Carroll,
J. D., et al. (2010). Effect of pulsing in low-level light therapy. Lasers Surg. Med.
42, 450–466. doi: 10.1002/lsm.20950
Heenen, M., Galand, P., de Maertelaer, V., and Heenen, P. H. (1987). Psoriasis:
hyperproliferation cannot induce characteristic epidermal morphology. Cell
Tissue Kinet. 20, 561–570. doi: 10.1111/j.1365-2184.1987.tb01365.x
Heenen,M., Thiriar, S., Noël, J. C., andGaland, P. (1998). Ki-67 immunostaining of
normal human epidermis: comparison with 3H-thymidine labelling and PCNA
immunostaining. Dermatol. Basel Switz. 197, 123–126. doi: 10.1159/000017982
Hoath, S. B., and Leahy, D. G. (2003). The organization of human epidermis:
functional epidermal units and phi proportionality. J. Invest. Dermatol. 121,
1440–1446. doi: 10.1046/j.1523-1747.2003.12606.x
Kessel, K. A., Habermehl, D., Jäger, A., Floca, R. O., Zhang, L., Bendl, R.,
et al. (2013). Development and validation of automatic tools for interactive
recurrence analysis in radiation therapy: optimization of treatment algorithms
for locally advanced pancreatic cancer. Radiat. Oncol. Lond. Engl. 8:138.
doi: 10.1186/1748-717X-8-138
Klein, A.M., Nikolaidou-Neokosmidou, V., Doupé, D. P., Jones, P. H., and Simons,
B. D. (2011). Patterning as a signature of human epidermal stem cell regulation.
J. R. Soc. Interface 8, 1815–1824. doi: 10.1098/rsif.2011.0240
Frontiers in Physiology | www.frontiersin.org 16 January 2017 | Volume 8 | Article 28
Félix Garza et al. Dynamic Model of Blue Light Treatment
Kleinpenning, M. M., Otero, M. E., van Erp, P. E. J., Gerritsen, M. J. P., and
van de Kerkhof, P. C. M. (2012). Efficacy of blue light vs. red light in the
treatment of psoriasis: a double-blind, randomized comparative study: blue
light versus red light in psoriasis. J. Eur. Acad. Dermatol. Venereol. 26, 219–225.
doi: 10.1111/j.1468-3083.2011.04039.x
Kleinpenning, M. M., Smits, T., Frunt, M. H., van Erp, P. E., van de Kerkhof,
P., and Gerritsen, R. M. (2010). Clinical and histological effects of blue
light on normal skin. Photodermatol. Photoimmunol. Photomed. 26, 16–21.
doi: 10.1111/j.1600-0781.2009.00474.x
Lapchak, P. A., Salgado, K. F., Chao, C. H., and Zivin, J. A. (2007).
Transcranial near-infrared light therapy improves motor function following
embolic strokes in rabbits: an extended therapeutic window study using
continuous and pulse frequency delivery modes. Neuroscience 148, 907–914.
doi: 10.1016/j.neuroscience.2007.07.002
Lee, C.-H., Wu, S.-B., Hong, C.-H., Yu, H.-S., and Wei, Y.-H. (2013). Molecular
mechanisms of UV-induced apoptosis and its effects on skin residential cells:
the implication in UV-based phototherapy. Int. J. Mol. Sci. 14, 6414–6435.
doi: 10.3390/ijms14036414
Liebmann, J., Born, M., and Kolb-Bachofen, V. (2010). Blue-light irradiation
regulates proliferation and differentiation in human skin cells. J. Invest.
Dermatol. 130, 259–269. doi: 10.1038/jid.2009.194
Maari, C., Viau, G., and Bissonnette, R. (2003). Repeated exposure to blue
light does not improve psoriasis. J. Am. Acad. Dermatol. 49, 55–58.
doi: 10.1067/mjd.2003.445
Marino, S., Hogue, I. B., Ray, C. J., and Kirschner, D. E. (2008). A methodology
for performing global uncertainty and sensitivity analysis in systems biology. J.
Theor. Biol. 254, 178–196. doi: 10.1016/j.jtbi.2008.04.011
Markovitsi, D. (2016). UV-induced DNA damage: the role of electronic excited
states. Photochem. Photobiol. 92, 45–51. doi: 10.1111/php.12533
Monfrecola, G., Lembo, S., Cantelli, M., Ciaglia, E., Scarpato, L., Fabbrocini, G.,
et al. (2014). The effect of visible blue light on the differentiation of dendritic
cells in vitro. Biochimie 101, 252–255. doi: 10.1016/j.biochi.2014.02.001
Ng, C. M., Joshi, A., Dedrick, R. L., Garovoy, M. R., and Bauer, R. J.
(2005). Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab
in patients with moderate to severe psoriasis. Pharm. Res. 22, 1088–1100.
doi: 10.1007/s11095-005-5642-4
Oh, P.-S., Hwang, H., Jeong, H.-S., Kwon, J., Kim, H.-S., Kim, M., et al.
(2016). Blue light emitting diode induces apoptosis in lymphoid
cells by stimulating autophagy. Int. J. Biochem. Cell Biol. 70, 13–22.
doi: 10.1016/j.biocel.2015.11.004
Opländer, C., Deck, A., Volkmar, C. M., Kirsch, M., Liebmann, J., Born, M.,
et al. (2013). Mechanism and biological relevance of blue-light (420–453nm)-
induced nonenzymatic nitric oxide generation from photolabile nitric oxide
derivates in human skin in vitro and in vivo. Free Radic. Biol. Med. 65,
1363–1377. doi: 10.1016/j.freeradbiomed.2013.09.022
Parisi, R., Symmons, D. P., Griffiths, C. E., Ashcroft, D. M., and Identification and
Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
(2013). Global epidemiology of psoriasis: a systematic review of incidence and
prevalence. J. Invest. Dermatol. 133, 377–385. doi: 10.1038/jid.2012.339
Pathak, M. A. (1991). Ultraviolet radiation and the development of non-
melanoma andmelanoma skin cancer: clinical and experimental evidence. Skin
Pharmacol. 4(Suppl. 1), 85–94.
Perera, G. K., Di Meglio, P., and Nestle, F. O. (2012). Psoriasis. Annu. Rev. Pathol.
7, 385–422. doi: 10.1146/annurev-pathol-011811-132448
Pfaff, S., Liebmann, J., Born, M., Merk, H. F., and von Felbert, V. (2015).
Prospective randomized long-term study on the efficacy and safety of uv-
free blue light for treating mild Psoriasis Vulgaris. Dermatology 231, 24–34.
doi: 10.1159/000430495
Sadeghian, K., Bocola, M., and Schütz, M. (2008). A conclusive mechanism of the
photoinduced reaction cascade in blue light using flavin photoreceptors. J. Am.
Chem. Soc. 130, 12501–12513. doi: 10.1021/ja803726a
Savill, N. J. (2003). Mathematical models of hierarchically structured cell
populations under equilibrium with application to the epidermis. Cell Prolif.
36, 1–26. doi: 10.1046/j.1365-2184.2003.00257.x
Schneider, L. A., Hinrichs, R., and Scharffetter-Kochanek, K. (2008).
Phototherapy and photochemotherapy. Clin. Dermatol. 26, 464–476.
doi: 10.1016/j.clindermatol.2007.11.004
Shnitkind, E., Yaping, E., Geen, S., Shalita, A. R., and Lee, W.-L. (2006). Anti-
inflammatory properties of narrow-band blue light. J. Drugs Dermatol. 5,
605–610.
Simonart, T., Heenen, M., and Lejeune, O. (2010). Epidermal kinetic alterations
required to generate the psoriatic phenotype: a reappraisal: kinetic alterations
in psoriasis. Cell Prolif. 43, 321–325. doi: 10.1111/j.1365-2184.2010.00672.x
Sparsa, A., Faucher, K., Sol, V., Durox, H., Boulinguez, S., Doffoel-Hantz, V.,
et al. (2010). Blue light is phototoxic for B16F10 murine melanoma and bovine
endothelial cell lines by direct cytocidal effect. Anticancer Res. 30, 143–147.
Taoufik, K., Mavrogonatou, E., Eliades, T., Papagiannoulis, L., Eliades, G., and
Kletsas, D. (2008). Effect of blue light on the proliferation of human gingival
fibroblasts. Dent. Mater. 24, 895–900. doi: 10.1016/j.dental.2007.10.006
van Gemert, M. J., Jacques, S. L., Sterenborg, H. J., and Star, W. M. (1989). Skin
optics. IEEE Trans. Biomed. Eng. 36, 1146–1154. doi: 10.1109/10.42108
Wataha, J. C., Lewis, J. B., Lockwood, P. E., Noda, M., Messer, R. L., and Hsu, S.
(2008). Response of THP-1 monocytes to blue light from dental curing lights. J.
Oral Rehabil. 35, 105–110. doi: 10.1111/j.1365-2842.2007.01806.x
Watt, F. M. (2014). Mammalian skin cell biology: at the interface between
laboratory and clinic. Science 346, 937–940. doi: 10.1126/science.1253734
Weatherhead, S. C., Farr, P. M., Jamieson, D., Hallinan, J. S., Lloyd, J. J., Wipat,
A., et al. (2011). Keratinocyte apoptosis in epidermal remodeling and clearance
of psoriasis induced by UV radiation. J. Invest. Dermatol. 131, 1916–1926.
doi: 10.1038/jid.2011.134
Weatherhead, S. C., Farr, P. M., and Reynolds, N. J. (2013). Spectral effects of UV
on psoriasis. Photochem. Photobiol. Sci. 12, 47–53. doi: 10.1039/C2PP25116G
Weinstabl, A., Hoff-Lesch, S., Merk, H. F., and von Felbert, V. (2011). Prospective
randomized study on the efficacy of blue light in the treatment of psoriasis
vulgaris. Dermatology 223, 251–259. doi: 10.1159/000333364
Weinstein, G. D., McCullough, J. L., and Ross, P. A. (1985). Cell kinetic
basis for pathophysiology of psoriasis. J. Invest. Dermatol. 85, 579–583.
doi: 10.1111/1523-1747.ep12283594
Weinstein, G. D., and Van Scott, E. J. (1965). Autoradiographic analysis of turnover
times of normal and psoriatic epidermis. J. Invest. Dermatol. 45, 257–262.
doi: 10.1038/jid.1965.126
Yoshida, A., Yoshino, F., Makita, T., Maehata, Y., Higashi, K., Miyamoto, C., et al.
(2013). Reactive oxygen species production in mitochondria of human gingival
fibroblast induced by blue light irradiation. J. Photochem. Photobiol. B Biol. 129,
1–5. doi: 10.1016/j.jphotobiol.2013.09.003
Zhang, H., Hou, W., Henrot, L., Schnebert, S., Dumas, M., Heusèle, C., et al.
(2015). Modelling epidermis homoeostasis and psoriasis pathogenesis. J. R. Soc.
Interface 12. doi: 10.1098/rsif.2014.1071
Zhou, H., Hu, C., Zhu, Y., Lu, M., Liao, S., Yeilding, N., et al. (2010).
Population-based exposure-efficacy modeling of ustekinumab in patients
with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 50, 257–267.
doi: 10.1177/0091270009343695
Zonios, G., Bykowski, J., and Kollias, N. (2001). Skin melanin, hemoglobin,
and light scattering properties can be quantitatively assessed in vivo
using diffuse reflectance spectroscopy. J. Invest. Dermatol. 117, 1452–1457.
doi: 10.1046/j.0022-202x.2001.01577.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Félix Garza, Liebmann, Born, Hilbers and van Riel. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 17 January 2017 | Volume 8 | Article 28
